Discovery of compounds inhibiting SARS-COV-2 multi-targets

J Biomol Struct Dyn. 2023 Apr;41(6):2602-2617. doi: 10.1080/07391102.2021.2025149. Epub 2022 Jan 7.


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic that has devastated the lives of millions. Researchers around the world are relentlessly working in hopes of finding a cure. Even though the virus shares similarities with reported SARS-CoV and MERS-CoV at the genomic and proteomic level, efforts to repurpose already known drugs against SARS-CoV-2 have resulted ineffective. In this succinct review, we discuss the different potential targets in SARS-CoV-2 at both the genomic and proteomic levels. In addition, we analyze the compounds inhibiting individual target protein as well as multiple targets of SARS-CoV-2. ACE-2 receptor in humans has also been considered a target, keeping the role of the receptor in mind. The mechanism of action of these compounds has also been highlighted along with their clinical manifestation. Towards the end of the review, a brief note on the drugs currently in clinical trials and the current status of the vaccines are also examined. In conclusion, compounds targeting multiple targets of the virus hold the key in putting an end to the coronavirus malady.Communicated by Ramaswamy H. Sarma.

Keywords: ACE-2; SARS-CoV-2; drug targets; inhibitors; multi-targets.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • COVID-19*
  • Humans
  • Middle East Respiratory Syndrome Coronavirus* / metabolism
  • Proteomics
  • SARS-CoV-2


  • Antiviral Agents